References
- Kater AP, Tonino SH, Egle A, et al. How does lenalidomide target the chronic lymphocytic leukemia microenvironment? Blood 2014;124:2184–2189.
- Giannopoulos K, Mertens D, Stilgenbauer S. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. Expert Opin Pharmacother 2011;12:2857–2864.
- Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immuno-modulatory drug. Haematologica 2009;94:1198–1202.
- Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010;47:115–123.
- D’Arena G, Musto P, Cascavilla N, et al. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol 2000;64:275–281.
- Badoux XC, Keating MJ, Wen S, et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2013;31:584–591.
- Lapalombella R, Yu B, Triantafillou G, et al. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112:5180–5189.
- Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumor activity of rituximab in vivo. Br J Haematol 2007;140:36–45.
- Gaidarova S, Mendy D, Heise C, et al. Lenalidomide induces capping of CD20 and cytoskeleton proteins to enhance rituximab immune recognition of malignant B-cells. Blood 2010;116(Suppl. 1): Abstract 2845.